Current stock page

Financial Data

HAE Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

HAEHaemonetics Corporation

Healthcare / Medical - Devices

Leader

Sector Leader

BullishEdge 10/10
$122.86+$1.94 (+1.60%)

Latest quote

  • Momentum
    91
  • Value
    60
  • Quality
    77
  • Risk resilience
    67
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 26, 2026, compared with the same quarter a year earlier.

Revenue
$357.76M
+9.3% YoY
Net income
$46.31M
+19.7% YoY
Free cash flow
$118.89M
+11.8% YoY
Operating margin
21.0%
+0.4 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

HAE, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+9.3%$358M$339M$346M$339M$327M$321M$331M$349M
Gross profit+20.4%$221M$203M$198M$191M$183M$192M$182M$200M
Operating income+11.7%$75M$57M$51M$70M$67M$54M$51M$59M
Net income+19.7%$46M$33M−$20M$45M$39M$34M$58M$37M
EPS (diluted)+23.5%$1.00$0.72−$0.44$0.95$0.81$0.70$1.17$0.74
Gross margin+5.7 pts61.7%59.8%57.2%56.5%56.0%59.7%55.0%57.4%
Operating margin+0.4 pts21.0%16.9%14.9%20.5%20.6%16.8%15.6%16.9%
Net margin+1.1 pts12.9%9.7%-5.8%13.2%11.8%10.6%17.5%10.8%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow+15.1%$128M$52M$71M$94M$111M$17M$117M$44M
Capital expenditure−83.5%−$9M−$8M−$18M−$6M−$5M−$4M−$16M−$9M
Free cash flow+11.8%$119M$44M$53M$87M$106M$14M$101M$35M
Free cash flow margin+0.8 pts33.2%13.1%15.4%25.7%32.5%4.2%30.5%10.1%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets−1.3%$2.41B$2.37B$2.40B$2.49B$2.44B$2.46B$2.45B$2.53B
Total liabilities−5.1%$1.51B$1.53B$1.60B$1.58B$1.59B$1.58B$1.63B$1.62B
Shareholders' equity+5.8%$898M$837M$796M$911M$849M$882M$821M$907M
Total debt−8.2%$1.12B$1.17B$1.22B$1.22B$1.22B$1.22B$1.22B$1.22B
Cash and equivalents−12.0%$261M$223M$245M$363M$296M$293M$307M$321M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/E ratio+34.6153.6340.3628.2917.4119.0216.4719.7524.52
P/B ratio+2.436.204.643.463.353.773.054.033.52
Return on equity−8.2 pts11.6%11.5%12.2%19.2%19.8%18.5%20.4%14.3%
Debt to equity−0.191.251.401.541.341.441.391.491.35
Free cash flow yield−2.6 pts5.5%7.5%9.5%10.1%8.0%7.0%4.3%3.0%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio53.27x
P/B ratio6.12x
Revenue growth (YoY)9.30%
EPS growth (YoY)25.93%
Gross margin58.83%
Operating margin18.34%
ROE12.07%
ROIC8.75%
Debt to equity1.25
FCF yield5.52%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$122.86
Volume
As of Nov 13, 2026
439,697
RSI (14)
As of Nov 13, 2026
58.75
MACD
As of Nov 13, 2026
2.53
MACD signal
As of Nov 13, 2026
2.89
MACD histogram
As of Nov 13, 2026
-0.36
ADX (14)
As of Nov 13, 2026
38.62
SMA (50)
As of Nov 13, 2026
$113.31
SMA (200)
As of Nov 13, 2026
$81.26
ATR (14)
As of Nov 13, 2026
$4.42
Historical volatility (annualized)
As of Nov 13, 2026
33.10%
Volume (20-day average)
As of Nov 13, 2026
685,219
Risk measures
MetricValue
Resilience score67/100
Beta0.24
Annual volatility41.04%
Max drawdown-40.06%
Sharpe ratio1.35
VaR (95%, 1-day)-3.09%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

HAE Financial Data FAQ

What is Haemonetics Corporation's revenue?

Haemonetics Corporation's revenue is one of the core financial data points for HAE. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Haemonetics Corporation's revenue growing?

Revenue growth shows whether Haemonetics Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is HAE's EPS?

HAE's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Haemonetics Corporation's net income?

Haemonetics Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Haemonetics Corporation generate?

Free cash flow shows how much cash Haemonetics Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Haemonetics Corporation have?

Cash and debt help frame HAE's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.